<DOC>
	<DOCNO>NCT00796757</DOCNO>
	<brief_summary>This single arm study assess progression free survival , tumor response safety Avastin combination interferon alfa-2a ( IFN ) first line treatment patient metastatic clear cell renal cell carcinoma . Patients receive Avastin ( 10mg/kg iv ) every 2 week combination low dose interferon alfa-2a ( 3 MIU sc three time per week ( t.i.w. ) . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Low-Dose-Interferon Patients With Metastatic Clear Cell Renal Cell Carcinoma ( RCC ) .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; metastatic RCC majority ( &gt; 50 % ) conventional clearcell type ; prior total nephrectomy primary RCC ; least one measurable nonmeasurable lesion ; ECOG performance score 0 2. prior systemic treatment metastatic RCC ; current previously treat nonstable CNS metastases spinal cord compression ; major surgery ( include open biopsy ) radiation therapy within 28 day prior enrollment ; significant cardiovascular disease within 6 month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>